

2020 年 業績

英文論文

1. Shiota M, Fujimoto N, Yamamoto Y, Takeuchi A, Tatsugami K, Uchiumi T, Matsuyama H, Eto M.
Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer.
Cancer Immunol Immunother. 2020 Mar 2. doi: 10.1007/s00262-020-02533-8
2. Shiota M, Endo S, Fujimoto N, Tsukahara S, Ushijima M, Kashiwagi E, Takeuchi A, Inokuchi J, Uchiumi T, Masatoshi Eto M.
Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy.
Urologic Oncology. 2020 Nov;38(11):849.e11-849.e18
3. Endo S, Oguri H, Segawa J, Kawai M, Hu D, Xia S, Okada T, Irie K, Fujii S, Gouda H, Iguchi K, Matsukawa T, Fujimoto N, Nakayama T, Toyooka N, Matsunaga T, Ikari A.
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
Journal of Medicinal Chemistry. 2020;63(18):10396–10411
4. Hamasuna R, Aono H, Kawaguchi K, Matsumoto M, Fujimoto N.
Sensitivity of a transcription-mediated amplification method (Aptima *Mycoplasma genitalium* assay) to detect *M. genitalium* in vitro.
Journal of Infection and Chemotherapy. 2020 Dec 1; S1341-321X(20)30417-7.
doi:10.1016/j.jiac.2020 Nov.010. Online ahead of print.
5. Togo Y, Fukui K, Ueda Y, Kanamaru S, Shimizu Y, Wada K, Sadahira T, Yamada Y, Matsumoto M, Hamasuna R, Ishikawa K, Takai M, Maekawa Y, Yasuda M, Kokura K, Kondoh N, Takiuchi H, Yamamoto S.
Comparison of single- and multiple-dose cefazolin as prophylaxis for transurethral enucleation of prostate: A multicenter, prospective, randomized controlled trial by the Japanese Research Group for Urinary Tract Infection.

International Journal of Urology. 2020; 27(3):244-248.

6. Fujimoto N, Shiota M, Matsukawa T, Minato A, Tomisaki I, Ohnishi R, Eto M.
Three-months Prostate-specific Antigen Level After Androgen Deprivation Therapy Predicts Survival in Patients with Metastatic Castration-sensitive Prostate Cancer.
In Vivo. 35: doi: 10.21873/invivo.11xxx

7. Minato A, Noguchi H, Ohnishi R, Tomisaki I, Fujimoto N.
Reduced Expression Level of GPX2 in T1 Bladder Cancer and Its Role in Early Phase Invasion of Bladder Cancer.
In Vivo.in press

8. Kobayashi K, Yamamoto S, Takahashi S, Ishikawa K, Yasuda M, Wada K, Hamasuna R, Hayami H, Manimitani S, Matsumoto T, Kiyota H, Tateda H, Saro J, Hanaki H, Masumori N, Hiyama H, Yamada H, Egawa S, Kimura T, Nishiyama H, Miyazaki J, Mastumoto K, Homma Y, Kamei J, Fujimoto K, Torimoto K, Tanaka K, Togo Y, Uehara S, Matsubara A, Shoji K, Goto H, Komeda H, Ito T, Mori K, Mita K, Kato M, Fujimoto Y, Masue T, Inatomi H, Takahashi Y, Ishihara S, Nishimura K, Mitsumori K, Ito N, Kanamaru S, Yamada D, Maeda H, Yamashita M, Tsugawa M, Takenaka T, Takahashi K, Oka Y, Yasufuku T, Watanabe S, CHihara Y, Okumura K, Kawanishi H, Matsukawa M, Shigeta M, Koda S.
The third national Japanese antimicrobial susceptibility pattern surveillance program: bacterial isolates from complicated urinary tract infection patients
Journal of Infection and Chemotherapy. 2020 5;26: 418-428,

9. Nagata Y, Kawahara T, Goto T, Inoue S, Teramoto Y, Jiang G, Fujimoto N, Miyamoto H.
Effects of α 1-adrenergic receptor antagonists on the development and progression of urothelial cancer.
American Journal Cancer Research. 2020 10(12):4386-4398

10. Nagata Y, Goto T, Jiang G, Teramoto Y, Miyamoto H.
 5α -Reductase Inhibitors Do Not Prevent the Development and Progression of Urothelial Cancer: *In Vitro* Evidence.
Bladder Cancer. 2020;6(4):481-488.

11. Sharma M, Nagata Y, Yang Z, Miyamoto H.

The impact of routine frozen section analysis during partial cystectomy for bladder cancer on surgical margin status and long-term oncologic outcome.

Urologic Oncology. 2020 May 8:S1078-1439(20)30140-X.

doi: 10.1016/j.urolonc.2020.04.012.

12. Ide H, Goto T, Teramoto Y, Mizushima T, Jiang G, Nagata Y, Inoue S, Baras AS, Kashiwagi E, Miyamoto H.
FOXO1 inactivation induces cisplatin resistance in bladder cancer.
Cancer Science. 2020 Sep;111(9):3397-3400.
13. Goto T, Kashiwagi E, Jiang G, Nagata Y, Teramoto Y, Baras AS, Yamashita S, Ito A, Arai Y, Miyamoto H.
Estrogen receptor- β signaling induces cisplatin resistance in bladder cancer.
American Journal of Cancer Research. 2020 Aug 1;10(8):2523-2534.
14. Ide H, Mizushima T, Jiang G, Goto T, Nagata Y, Teramoto Y, Inoue S, Li Y, Kashiwagi E, Baras AS, Netto GJ, Kawahara T, Miyamoto H.
FOXO1 as a tumor suppressor inactivated via AR/ER β signals in urothelial cells.
Endocrine- Related Cancer. 2020 Apr;27(4):231-244.
15. Ide H, Inoue S, Mizushima T, Jiang G, Nagata Y, Goto T, Kashiwagi E, Miyamoto H.
Compound A inhibits urothelial tumorigenesis via both the androgen receptor and glucocorticoid receptor signaling pathways.
American Journal of Translation Research. 2020;12(5):1779-1788.
16. Ide H, Inoue S, Mizushima T, Jiang G, Goto T, Nagata Y, et al.
Identification of FOXO1 as a tumor suppressor modulated by androgen receptor/estrogen receptor- β signals: Implications for bladder cancer promotion and chemoresistance, July 2020,
European Urology Open Science 19:e417, DOI: 10.1016/S2666-1683(20)32840-8
17. Matsumoto M, Yamamoto S.
Acute bacterial prostatitis. Asian Guidelines for UTIs & STIs, the 2nd Edition, 2020.
Asian Association of UTI/STI(AAUS).
http://guidelines.aaus.info/aaus/index.php/Main_Page

18. Wada K, Hamasuna R.

The 2nd edition AAUS guideline, Sexually Transmitted Infection, Mycoplasma and non-chlamydial non-gonococcal urethritis

Asian guideline for UT I& STI by Asian Association of UTI/STI

19. Nagata Y, Miyamoto H.

The prognostic role of steroid hormone receptor signaling pathways in urothelial carcinoma.

Transl Cancer Res 2020;9(10):6596-6608

20. Tomisaki I, Matsuyama A, Jotatsu M, Yamamura S, Onishi R, Fujimoto N.

Primary retroperitoneal mucinous cystadenocarcinoma with transition from the mesothelium.

IJU Case Rep. 2020 <https://doi.org/10.1002/iju5.12169>.